LB PHARMACEUTICALS INC 8-K

What Happened
LB Pharmaceuticals Inc. announced two leadership changes in an 8-K filed March 10, 2026. On March 6, 2026 the Board appointed Dr. Robert A. Lenz as a Class I director (term expiring at the 2026 annual meeting) and named him to the Nominating and Corporate Governance Committee. Separately, on March 4, 2026 the Board approved the promotion of Gad Soffer from Chief Business Officer to Chief Operating and Business Officer, effective immediately.

Key Details

• Dr. Robert A. Lenz appointment: effective March 6, 2026; Class I director through the 2026 annual meeting; member of the Nominating & Corporate Governance Committee.
• Director compensation for Dr. Lenz: $40,000 annual retainer + $5,000 committee retainer; initial stock option to purchase 20,000 shares (vesting in equal annual installments over 3 years); annual stock option grant of 10,000 shares (vests on earlier of 1 year or next annual meeting).
• Gad Soffer promotion: approved March 4, 2026; employment at-will; new annual base salary $505,000 and eligible for an annual bonus with a 40% target of base salary.
• Corporate governance items: Dr. Lenz will enter the company’s standard director indemnification and advancement agreement; the company reported no family relationships or related-party transactions requiring disclosure.

Why It Matters
These are governance and management-level changes that can affect oversight and operating execution. The board appointment adds a new director who will participate in governance decisions and receives equity-based compensation (stock options), which can modestly increase potential dilution and non-cash compensation expense. The promotion of Gad Soffer centralizes operating and business responsibilities under an executive whose pay was increased, which raises recurring personnel costs (salary and bonus potential) and signals continuity in the company’s senior management team. A press release dated March 9, 2026 regarding the director appointment was furnished under Regulation FD.